You don't need to be signed in to read BMJ Blogs, but you can register here to receive updates about other BMJ products and services via our site.

Interviews

Professor Jane Salmon about the PROMISSE study

15 Apr, 16 | by Ioannis Parodis

Dr. Jane Salmon is a Professor of Medicine and Professor of Obstetrics and Gynecology at Weill Cornell Medical College and the Collette Kean Research Professor at Hospital for Special Surgery in New York, USA. She is the principle investigator in the PROMISSE study, which has generated very important data and received great attention. 

– Professor Jane Salmon, what does the acronym PROMISSE stand for?

– PROMISSE stands for Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus study. PROMISSE is the largest multicenter, multiethnic, and multiracial study to prospectively assess the frequency of adverse pregnancy outcomes and clinical and laboratory variables (including research biomarkers) that predict them, in women with or without high titer antiphospholipid antibodies (APL) and inactive SLE or mild or moderate SLE activity at conception. We enrolled over 700 patients from 2003 to 2014.

 

more…

Post ACR 2015: Professor Richard Furie about anifrolumab

30 Nov, 15 | by Ioannis Parodis

Professor Richard Furie is the chief of the Division of Rheumatology of the North Shore-Long Island Jewish Health System in New York. His research in the field of SLE is profound. At the 2015 ACR Annual Meeting in San Francisco, professor Furie presented results from a phase II trial of anifrolumab, a type I IFN receptor antagonist.

 

– Professor Furie, what is your general impression about this upcoming medication?

Never before have we seen such a successful phase II study in SLE. The magnitude, consistency, and breadth of responses were quite striking. Although the primary endpoint was a composite of the SRI at Day 169 and the requirement by Day 85 to reduce the prednisone dose to <10 mg/day (and not exceed the Day 1 dose) and sustain this dose until Day 169, other successful outcomes included the SRI without the steroid taper requirement, the BICLA, modified SRI’s, CLASI, and steroid tapering (300 mg group only).  The results were more dramatic in those subjects with high baseline IFN gene signatures.  If the same degree of efficacy occurs in phase III, the lupus community will have another drug.

  more…

Professor Ronald van Vollenhoven about Lupus Science & Medicine

21 Sep, 15 | by Ioannis Parodis

Professor Ronald van Vollenhoven is the Head of the Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) at Karolinska Institutet in Stockholm, Sweden, and one of the Editors-in-chief for Lupus Science & Medicine.

 

– Professor van Vollenhoven, we have heard you many times encouraging the rheumatologists to treat to target, both for rheumatoid arthritis and for systemic lupus erythematosus. Remission is the obvious target in RA. What is the target in SLE?

– In SLE it’s a bit more complicated because there really are several targets. Remission can be the primary target but we also have to achieve improvements in HQ-QOL, prevent flares, prevent lupus-related damage, and minimize glucocorticoid exposure.

more…

Lupus Science & Medicine latest news

Lupus Science & Medicine latest news